

Nuclear Medicine Software Market by Software (Image Management, Workflow, PACS, Dosimetry, Treatment, AI/Analytics), Application (Diagnosis, Treatment, Theranostics, Research), Disease (Onco, Neuro, Cardio), End User & Region - Global Forecast to 2030

<https://marketpublishers.com/r/N6E36520B749EN.html>

Date: July 2025

Pages: 465

Price: US\$ 4,950.00 (Single User License)

ID: N6E36520B749EN

Abstracts

The nuclear medicine software market was valued at USD 970.03 million in 2025 and is estimated to reach USD 1,491.6 million by 2030, registering a CAGR of 9.0% during the forecast period. Growth in the nuclear medicine software market is being influenced by a convergence of clinical and technological advancements, along with favorable regulatory and reimbursement frameworks in developed and developing nations. These technological advancements are significantly transforming how nuclear medicine imaging and radiopharmaceutical therapies are delivered. Key factors driving growth include the increasing demand for accurate image analysis, PACS integration, dosimetry, treatment planning, advanced analytics, and reporting. In addition to the growing demand in the diagnostic imaging segment, nuclear medicine therapeutic applications are seeing an increase in the adoption rates of theranostics. Leading market players are increasingly integrating their solutions with AI-powered tools for tumor segmentation and automated reporting, thereby enhancing diagnostic accuracy and workflow efficiency. The pharmaceutical and life sciences sectors are fueling the demand for advanced nuclear medicine software solutions due to the expanding pipeline of radiopharmaceuticals. Furthermore, the growing transition towards cloud-native PACS integration and remotely accessible solutions is promoting the development of advanced software solutions. However, the growth of this market is moderately restrained due to challenges arising from data security, inadequate infrastructure, and radiation exposure.

“Cloud-native platforms are expected to register the fastest growth over the forecast

period.”

The lucrative growth of cloud-native platforms is attributed to the increasing demand for remote access, interoperability, and scalability across healthcare systems. Nuclear medicine is rapidly evolving through multi-center collaborations and AI-powered analytics, driving the need for cloud-native solutions. These platforms enable real-time data sharing, faster software updates, and enhanced cybersecurity features. Furthermore, healthcare systems are transitioning towards a value-based care approach, in which cloud-developed infrastructure supports integrated decision-making, thereby enhancing overall patient care. Moreover, the adoption of advanced nuclear medicine workflows requires cloud-based software platforms that can synchronize imaging and treatment planning. Some companies offering cloud-native platforms include Sectra’s Cloud Imaging Platform and Intelrad’s IntelePACS Cloud. These solutions support PET/SPECT viewing and reporting, seamlessly integrating with AI modules for remote accessibility.

“The subscription-based/Software-as-a-service (SaaS) models segment held the largest share of the nuclear medicine software market in 2024.”

The subscription-based Software-as-a-Service (SaaS) model segment dominates the software licensing segment in the nuclear medicine software market in 2024. This dominance is due to the lower upfront costs, flexibility, and cloud-based deployments offered by this model. Healthcare providers, life sciences companies, and research institutes are increasingly shifting from traditional perpetual licensing models because of the high capital expenditures and limited scalability associated with them. SaaS models provide regular software updates with predictable operational costs and seamlessly integrate with cloud-native PACS and radiology systems, thereby supporting hospitals and imaging centers in modernizing their nuclear imaging workflows. With the expansion of multi-site imaging networks, SaaS platforms enable centralized data access, interoperable workflows, and remote access diagnostics. Some of the leading market players offering their solutions through subscription-based SaaS models are GE Healthcare and Siemens Healthineers.

“North America market accounts for the largest share in the nuclear medicine software market in 2024.”

The North American market dominated the nuclear medicine software sector in 2024, due to its advanced healthcare infrastructure, increasing adoption of hybrid imaging systems, and strong regulatory support for radiopharmaceutical-based diagnostics and

therapeutics. Additionally, the significant presence of market leaders such as GE Healthcare and Siemens Healthineers contributes to the growth of the North American market. In contrast, the Asia Pacific market is expected to register the fastest growth rate over the forecast period. This growth is attributed to rising public and private investments in precision medicine, an escalating disease burden from cancer and cardiovascular diseases, and advancements in infrastructure across China, India, Japan, Australia, and South Korea. Furthermore, the region is experiencing rapid adoption of personalized dosimetry and theranostics, alongside increasing partnerships between local hospitals and globally established companies. Growing patient awareness, rising healthcare IT expenditure, and the increasing adoption of AI-based imaging solutions are further boosting growth in the Asia Pacific market.

In-depth interviews have been conducted with chief executive officers (CEOs), Directors, and other executives from various key organizations operating in the nuclear medicine software marketplace.

The breakdown of primary participants is as mentioned below:

By Company Type - Tier 1 (31%), Tier 2 (31%), and Tier 3 (28%)

By Designation - C-level Executives (44%), Director-level (31%), and Managers (25%)

By Region - North America (45%), Europe (28%), Asia Pacific (20%), Latin America (4%), and Middle East & Africa (3%)

Key Players in the Nuclear Medicine Software Market

Prominent players in the nuclear medicine software market include include GE HealthCare (MIM Software Inc.)(US), Siemens Healthineers AG(Germay), Koninklijke Philips N.V. (Netherlands), Lantheus Holdings, Inc. (EXINI Diagnostics AB)(US), Brainlab AG(Germany), Mirada Medical(UK), DOSIsoft SA(France), Bracco Group (Italy), Hermes Medical Solutions (Sweden), INVIA, LLC (US), Mediso Ltd. (Hungary), Canon Medical Systems Corporation (Japan), LabLogic Systems Ltd. (UK), Mirion Technologies (ec2 Software Solutions)(US), COMECER S.p.A.(Italy), RaySearch Laboratories(Sweden), UltraSPECT Inc. (US), Sectra AB (Sweden), Agfa-Gevaert Group (Belgium), Perceptive(UK).

Players adopted both organic and inorganic growth strategies, including product launches and enhancements, as well as investments, partnerships, collaborations, joint ventures, funding, acquisitions, expansions, agreements, contracts, and alliances. These strategies aimed to increase their offerings, meet the unmet needs of customers, boost profitability, and expand their presence globally market.

The study includes an in-depth competitive analysis of these key players in the nuclear medicine software market, with their company profiles, recent developments, and key market strategies.

Research Coverage

The report studies the nuclear medicine software market based on software type, workflow, integration complexity, software licensing model, revenue model, application, therapeutic area, technology maturity, end user, and region.

The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.

The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.

The report studies micromarkets with respect to their growth trends, prospects, and contributions to the total nuclear medicine software market.

The report forecasts the revenue of market segments with respect to five major regions.

Reasons to Buy the Report

The report can help established firms, as well as new entrants/smaller firms, gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the five strategies mentioned below.

This report provides insights into the following pointers:

Analysis of key drivers (increasing demand for early and accurate diagnostics, growing focus on personalized medicine, integration of automated dosimetry tools, growing prevalence of chronic diseases and subsequent increase in clinical trials, effective monitoring of nuclear medicine software), restraints (high cost of imaging equipment, data privacy and security concerns, shortage of skilled professionals, interoperability issues), opportunities (infrastructure development, increased healthcare IT expenditure, data privacy and regulatory reforms), and challenges (compliance requirements, low penetration of advanced imaging devices, underdeveloped radiopharmacy ecosystem, economic and financial barriers) influencing the industry macrodynamics of nuclear medicine software market.

Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the nuclear medicine software market.

Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of nuclear medicine software across regions.

Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the nuclear medicine software market.

Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the nuclear medicine software market.

Contents

1 INTRODUCTION

- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
 - 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
 - 1.3.2 YEARS CONSIDERED
- 1.4 CURRENCY CONSIDERED
- 1.5 STAKEHOLDERS
- 1.6 LIMITATIONS

2 RESEARCH METHODOLOGY

- 2.1 RESEARCH APPROACH
 - 2.1.1 SECONDARY RESEARCH
 - 2.1.1.1 Key data from secondary sources
 - 2.1.2 PRIMARY RESEARCH
 - 2.1.2.1 Primary sources
 - 2.1.2.2 Key data from primary sources
 - 2.1.2.3 Breakdown of primaries
 - 2.1.2.4 Insights from primary experts
- 2.2 RESEARCH METHODOLOGY DESIGN
- 2.3 MARKET SIZE ESTIMATION
- 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.5 MARKET SHARE ESTIMATION
- 2.6 STUDY ASSUMPTIONS
- 2.7 RESEARCH LIMITATIONS
 - 2.7.1 METHODOLOGY-RELATED LIMITATIONS
- 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

- 4.1 OVERVIEW OF NUCLEAR MEDICINE SOFTWARE MARKET
- 4.2 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY & INTEGRATION COMPLEXITY

- 4.3 GEOGRAPHIC SNAPSHOT OF NUCLEAR MEDICINE SOFTWARE MARKET
- 4.4 NUCLEAR MEDICINE SOFTWARE MARKET: REGIONAL MIX
- 4.5 NUCLEAR MEDICINE SOFTWARE MARKET: DEVELOPED VS. EMERGING ECONOMIES

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

5.2.1 DRIVERS

- 5.2.1.1 Rising global disease prevalence
- 5.2.1.2 Surge in AI-powered theranostics
- 5.2.1.3 Adoption of cloud-based platforms & mobile/remote diagnostics
- 5.2.1.4 Radiopharmaceutical supply chain visibility & radiopharmaceutical software
- 5.2.1.5 Expansion of personalized medicine in nuclear applications

5.2.2 RESTRAINTS

- 5.2.2.1 High acquisition & total cost of ownership
- 5.2.2.2 Regulatory & approval delays with AI integration
- 5.2.2.3 Integration & interoperability challenges

5.2.3 OPPORTUNITIES

- 5.2.3.1 Precision & predictive dosimetry
- 5.2.3.2 Expansion of tele-nuclear medicine networks & mobile access

5.2.4 CHALLENGES

- 5.2.4.1 Lack of technical expertise
- 5.2.4.2 Regulatory uncertainties

5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

5.4 INDUSTRY TRENDS

5.4.1 OVERVIEW OF USE CASES

- 5.4.2 INTEGRATION OF ARTIFICIAL INTELLIGENCE AND ADVANCED ANALYTICS
- 5.4.3 SHIFT TOWARD HYBRID AND MULTI-MODALITY IMAGING SOLUTIONS

5.5 ECOSYSTEM ANALYSIS

5.6 SUPPLY CHAIN ANALYSIS

5.7 TECHNOLOGY ANALYSIS

5.7.1 KEY TECHNOLOGIES

- 5.7.1.1 SPECT/PET image reconstruction algorithms
- 5.7.1.2 Quantitative molecular imaging tools
- 5.7.1.3 Radiopharmaceutical dosimetry software
- 5.7.1.4 Artificial intelligence and machine learning
- 5.7.1.5 Multi-modality fusion & co-registration engines

5.7.2 COMPLEMENTARY TECHNOLOGIES

5.7.2.1 DICOM AND HL7 integration engines

5.7.2.2 Theranostics workflow orchestration tools

5.7.2.3 Cloud-based PACS/archiving solutions

5.7.3 ADJACENT TECHNOLOGIES

5.7.3.1 Molecular imaging-omics integration tools

5.7.3.2 Blockchain

5.8 REGULATORY ANALYSIS

5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

5.8.2 REGULATORY ANALYSIS

5.9 PRICING ANALYSIS

5.9.1 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY KEY PLAYER (2024)

5.9.2 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY REGION (2024)

5.9.3 PRICING MODELS (QUALITATIVE)

5.10 PORTER'S FIVE FORCES ANALYSIS

5.10.1 THREAT OF NEW ENTRANTS

5.10.2 THREAT OF SUBSTITUTES

5.10.3 BARGAINING POWER OF BUYERS

5.10.4 BARGAINING POWER OF SUPPLIERS

5.10.5 INTENSITY OF COMPETITIVE RIVALRY

5.11 PATENT ANALYSIS

5.11.1 PATENT PUBLICATION TRENDS FOR NUCLEAR MEDICINE SOFTWARE SOLUTIONS

5.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS

5.12 KEY STAKEHOLDERS & BUYING CRITERIA

5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS

5.12.2 BUYING CRITERIA

5.13 END-USER ANALYSIS

5.13.1 UNMET NEEDS

5.13.2 END-USER EXPECTATIONS

5.14 KEY CONFERENCES & EVENTS, 2025–2026

5.14.1 NUCLEAR MEDICINE SOFTWARE MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2025–2026

5.15 CASE STUDY ANALYSIS

5.15.1 ENSURING PRECISION IN NUCLEAR MEDICINE WITH NATIONAL STANDARD TRACEABILITY

5.15.1.1 Case 1: Strengthening quality control and patient outcomes with ANSTO's coordinated CRM program

5.15.2 STREAMLINING MULTI-MODALITY IMAGE FUSION FOR BETTER DIAGNOSTICS

5.15.2.1 Case 2: GE HealthCare's Xeleris platform enhances multi-modality imaging at a leading academic medical center

5.15.3 SUPPORTING REMOTE CONSULTATIONS WITH CLOUD-BASED NUCLEAR MEDICINE ANALYSIS

5.15.3.1 Case 3: Sectra's cloud-based solution empowers remote nuclear medicine consultations for regional hospitals

5.16 INVESTMENT & FUNDING SCENARIO

5.17 BUSINESS MODEL ANALYSIS

5.17.1 LICENSE-BASED BUSINESS MODELS

5.17.2 SUBSCRIPTION-BASED BUSINESS MODELS

5.17.3 SOFTWARE-AS-A-SERVICE (SAAS) BUSINESS MODELS

5.17.4 PAY-PER-USE BUSINESS MODELS

5.17.5 FREEMIUM BUSINESS MODELS

5.17.6 INTEGRATED SERVICE AND SOFTWARE BUNDLE BUSINESS MODELS

5.18 IMPACT OF AI/GEN AI ON NUCLEAR MEDICINE SOFTWARE MARKET

5.18.1 KEY USE CASES

5.18.2 CASE STUDIES OF AI/GENERATIVE AI IMPLEMENTATION

5.18.2.1 Case study 1: AI-based low-dose PET image reconstruction

5.18.2.2 Case study 2: Dose-aware diffusion models for 3D low-dose PET

5.18.3 IMPACT OF AI/GEN AI ON INTERCONNECTED AND ADJACENT ECOSYSTEMS

5.18.3.1 Medical image analysis software

5.18.3.2 Radiology information systems

5.18.3.3 Clinical decision support systems

5.18.4 USER READINESS & IMPACT ASSESSMENT

5.18.4.1 User readiness

5.18.4.1.1 User A: Healthcare providers

5.18.4.1.2 User B: Pharmaceutical & biotechnology companies

5.18.4.2 Impact assessment

5.18.4.2.1 User A: Healthcare providers

5.18.4.2.1.1 Implementation

5.18.4.2.1.2 Impact

5.18.4.2.2 User B: Pharmaceutical & biotechnology companies

5.18.4.2.2.1 Implementation

5.18.4.2.2.2 Impact

5.19 IMPACT OF 2025 US TARIFFS ON NUCLEAR MEDICINE SOFTWARE MARKET

5.19.1 INTRODUCTION

5.19.2 KEY TARIFF RATES

5.19.3 PRICE IMPACT ANALYSIS

5.19.4 IMPACT ON COUNTRY/REGION

5.19.4.1 US

5.19.4.2 Europe

5.19.4.3 Asia Pacific

5.19.5 IMPACT ON END-USE INDUSTRIES

6 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE

6.1 INTRODUCTION

6.2 IMAGE ACQUISITION & RECONSTRUCTION SOFTWARE

6.2.1 ABILITY TO OPTIMIZE NUCLEAR IMAGING THROUGH AI-POWERED ACQUISITION AND RECONSTRUCTION SOFTWARE TO DRIVE MARKET

6.3 IMAGE ANALYSIS & QUANTIFICATION SOFTWARE

6.3.1 AI INNOVATION, WORKFLOW OPTIMIZATION, AND PERSONALIZED CARE TRENDS TO SUPPORT GROWTH

6.4 WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE

6.4.1 NEED FOR ADVANCING NUCLEAR MEDICINE THROUGH INTEGRATED WORKFLOW MANAGEMENT SOLUTIONS TO BOOST GROWTH

6.5 PACS INTEGRATION & DATA MANAGEMENT SOFTWARE

6.5.1 GROWING NEED FOR RADIOTRACER-AWARE ANALYTICS, COMPLIANCE, AND INTEROPERABILITY TO BOOST ADOPTION

6.6 REPORTING & DOCUMENTATION SOFTWARE

6.6.1 EXPANDING HEALTHCARE INVESTMENTS IN APAC AND MIDDLE EAST TO ACCELERATE ADOPTION OF REPORTING & DOCUMENTATION SOFTWARE

6.7 RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE

6.7.1 OPERATIONAL, CLINICAL, AND REGULATORY CATALYSTS TO DRIVE MARKET GROWTH

6.8 DOSIMETRY & TREATMENT PLANNING SOFTWARE

6.8.1 PRECISION IMAGING AND AI-DRIVEN WORKFLOWS TO ADVANCE DOSIMETRY & TREATMENT PLANNING

6.9 QUALITY CONTROL & ASSURANCE SOFTWARE

6.9.1 HYBRID-IMAGING QA NEEDS, DIGITAL AUDIT READINESS, AND EDGE-BASED AI FOR OFFLINE ENVIRONMENTS TO FUEL GROWTH

6.10 AI & ADVANCED ANALYTICS SOFTWARE

6.10.1 ABILITY OF INTEGRATED AI ECOSYSTEMS TO REDEFINE NUCLEAR

IMAGING EFFICIENCY TO SUPPORT MARKET

6.11 MOBILE & REMOTE ACCESS SOFTWARE

6.11.1 GROWING POPULARITY OF PORTABLE AND POINT-OF-CARE SCANNERS TO DRIVE MARKET DEMAND

7 NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW

7.1 INTRODUCTION

7.2 IMAGE ACQUISITION

7.2.1 ADVANCED INNOVATIONS TRANSFORMING IMAGE ACQUISITION INTO DYNAMIC, MULTI-FUNCTIONAL COMPONENTS TO DRIVE MARKET

7.3 DATA PROCESSING

7.3.1 OPTIMIZING CLINICAL INSIGHTS WITH INTELLIGENT DATA PROCESSING IN NUCLEAR MEDICINE WORKFLOWS TO SUPPORT GROWTH

7.4 REPORTING

7.4.1 PRECISION AND EFFICIENCY ASSOCIATED WITH AI-INTEGRATED REPORTING SOLUTIONS TO TRANSFORM MARKET

7.5 DATA MANAGEMENT

7.5.1 GROWING NEED FOR ADVANCED DATA MANAGEMENT SOLUTIONS TO STREAMLINE IMAGING WORKFLOWS TO DRIVE GROWTH

8 NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY

8.1 INTRODUCTION

8.2 STANDALONE SOLUTIONS

8.2.1 AVAILABILITY OF ROBUST STANDALONE SOLUTIONS TAILORED TO SPECIFIC IMAGING AND ANALYSIS NEEDS TO BOOST MARKET

8.3 INTEGRATED SOLUTIONS

8.3.1 ADVANTAGES SUCH AS REDUCED MANUAL STEPS AND IMPROVED DIAGNOSTIC ACCURACY TO DRIVE DEMAND

8.4 CLOUD-NATIVE PLATFORMS

8.4.1 ABILITY OF CLOUD-NATIVE PLATFORMS TO DRIVE SCALABLE AND CONNECTED IMAGING IN NUCLEAR MEDICINE TO DRIVE MARKET

9 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING

9.1 INTRODUCTION

9.2 PERPETUAL/TRADITIONAL LICENSES

9.2.1 GROWING DEMAND FOR PREDICTABLE LONG-TERM COSTS TO DRIVE

ADOPTION

9.3 SUBSCRIPTION/SAAS LICENSES

9.3.1 ABILITY OF CLOUD-BASED SAAS SOLUTIONS TO ENHANCE IMAGING SCALABILITY AND EXPAND ACCESS TO FUEL GROWTH

9.4 USAGE-BASED LICENSES

9.4.1 ADVANTAGES SUCH AS SCALABLE ACCESS, REGULATORY COMPLIANCE, AND OPTIMIZED COSTS TO DRIVE DEMAND

9.5 ENTERPRISE AGREEMENTS

9.5.1 SEAMLESS DIGITAL TRANSFORMATION IN NUCLEAR MEDICINE THROUGH ENTERPRISE AGREEMENTS TO SUPPORT MARKET GROWTH

10 NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL

10.1 INTRODUCTION

10.2 SOFTWARE LICENSES

10.2.1 ADVANTAGES SUCH AS SCALABLE, AI-POWERED, AND COMPLIANT IMAGING SOLUTIONS TO DRIVE DEMAND

10.3 MAINTENANCE & SUPPORT

10.3.1 RELIABLE DIAGNOSTICS AND MINIMIZED DOWNTIME ASSOCIATED WITH MAINTENANCE & SUPPORT SERVICES TO BOOST MARKET

10.4 PROFESSIONAL SERVICES

10.4.1 OPTIMIZING PHARMACY OPERATIONS THROUGH COMPREHENSIVE AUTOMATION SERVICES TO DRIVE GROWTH

10.5 CLOUD SERVICES

10.5.1 ACCELERATING NUCLEAR MEDICINE TRANSFORMATION THROUGH CLOUD-DRIVEN IMAGING AND AI INTEGRATION TO BOOST MARKET

11 NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION

11.1 INTRODUCTION

11.2 DIAGNOSTICS

11.2.1 AUTOMATED IMAGE INTERPRETATION

11.2.1.1 Ability of AI-powered automated interpretation tools to streamline imaging workflows and reduce variability to boost adoption

11.2.2 TUMOR SEGMENTATION & QUANTIFICATION

11.2.2.1 Advancing precision oncology through AI-powered tumor segmentation solutions to support market growth

11.3 THERAPEUTICS

11.3.1 PREDICTIVE ANALYTICS

11.3.1.1 Advantages such as enhanced dosimetry accuracy and improved clinical outcomes to drive growth

11.3.2 WORKFLOW OPTIMIZATION & QUALITY CONTROL

11.3.2.1 Ability of workflow optimization and quality control solutions to enhance operational efficiency to boost market

11.3.3 PERSONALIZED DOSIMETRY CALCULATIONS

11.3.3.1 Optimized radiation delivery and standardized nuclear medicine workflows to drive demand

11.3.4 THERANOSTICS

11.3.4.1 Advantages such as real-time treatment optimization in nuclear medicine to drive popularity of theranostics

11.4 EMERGENCY & STAT WORKFLOWS

11.4.1 NEED TO ACCELERATE CRITICAL CARE DELIVERY WITH AI-DRIVEN NUCLEAR MEDICINE SOFTWARE SOLUTIONS TO PROPEL MARKET

11.5 CLINICAL RESEARCH

11.5.1 GROWING DEMAND FOR SCALABLE SERVICE SOLUTIONS THAT STREAMLINE IT DEPLOYMENT TO FURTHER MARKET GROWTH

12 NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA

12.1 INTRODUCTION

12.2 ONCOLOGY

12.2.1 GROWING NEED FOR CANCER DETECTION AND THERAPY PLANNING THROUGH MOLECULAR IMAGING MODALITIES TO DRIVE GROWTH

12.3 NEUROLOGY

12.3.1 ADVANTAGES SUCH AS EARLY DETECTION, FUNCTIONAL BRAIN MAPPING, AND AUTOMATED DISEASE TRACKING TO DRIVE DEMAND

12.4 CARDIOLOGY

12.4.1 NEED TO TRANSFORM CARDIAC NUCLEAR IMAGING WITH SMART TECHNOLOGIES TO BOOST GROWTH

12.5 OTHER THERAPEUTIC AREAS

13 NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY

13.1 INTRODUCTION

13.2 UPCOMING TECHNOLOGIES

13.2.1 AI & ADVANCED ANALYTICS

13.2.1.1 High burden of neurodegenerative diseases and oncology imaging complexity to boost market

13.2.2 DOSIMETRY & TREATMENT PLANNING

13.2.2.1 Rise of radioligand therapies like lutetium-177 to increase dosimetry software adoption

13.2.3 CLOUD-NATIVE PLATFORMS

13.2.3.1 Scalable AI-integrated nuclear medicine solutions with remote accessibility to drive nuclear medicine software growth

13.2.4 MOBILE & REMOTE ACCESS

13.2.4.1 Growing use of portable imaging devices, hybrid care demands, and supportive reimbursement trends to support market growth

13.3 MATURE TECHNOLOGIES

13.3.1 IMAGE ACQUISITION & RECONSTRUCTION

13.3.1.1 Ability of image reconstruction to drive precision and low-dose imaging in nuclear medicine to boost market

13.3.2 PACS INTEGRATION

13.3.2.1 Rise of hybrid imaging, need for SUV harmonization, and increasing regulatory focus on dosimetry to propel market

13.3.3 QUALITY CONTROL

13.3.3.1 Advancing quality control through standardized reconstruction in nuclear medicine to aid growth

14 NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER

14.1 INTRODUCTION

14.2 HEALTHCARE PROVIDERS

14.2.1 HOSPITALS

14.2.1.1 Ability of hospitals to drive diagnostic precision and workflow efficiency in nuclear medicine to boost market

14.2.2 OUTPATIENT SETTINGS

14.2.2.1 Need for accessibility, efficiency, and growth in nuclear medicine software to boost adoption

14.2.3 DIAGNOSTIC & IMAGING CENTERS

14.2.3.1 Expanding access and precision in nuclear diagnostics to support market growth

14.2.4 RADIOPHARMACIES

14.2.4.1 Accelerating radiopharmaceutical precision and safety through radiopharmacy software innovations to fuel growth

14.2.5 OTHER HEALTHCARE PROVIDERS

14.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES

14.3.1 EXPANDING INFLUENCE OF NUCLEAR MEDICINE SOFTWARE IN

RADIOPHARMACEUTICAL R&D AND CLINICAL TRIALS TO BOOST MARKET

14.4 MEDTECH COMPANIES

14.4.1 NEED TO ADVANCE NUCLEAR IMAGING TRIALS WITH PRECISION
SOFTWARE INTEGRATION TO PROPEL MARKET

14.5 OTHER END USERS

15 NUCLEAR MEDICINE SOFTWARE MARKET, BY REGION

15.1 INTRODUCTION

15.2 NORTH AMERICA

15.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA

15.2.2 US

15.2.2.1 Emergence of hybrid imaging systems with enhanced diagnostic accuracy to drive market growth

15.2.3 CANADA

15.2.3.1 Government initiatives and funding to support market growth

15.3 EUROPE

15.3.1 MACROECONOMIC OUTLOOK FOR EUROPE

15.3.2 GERMANY

15.3.2.1 Rising theranostic procedures to drive demand for advanced dosimetry and imaging software

15.3.3 UK

15.3.3.1 Infrastructure expansion and digital health initiatives to advance market growth

15.3.4 FRANCE

15.3.4.1 Accelerated digital transformation and expansion of targeted radiotherapy to drive growth

15.3.5 ITALY

15.3.5.1 Growing need for tailored diagnostics to drive nuclear medicine software market growth

15.3.6 SPAIN

15.3.6.1 Targeted public investments to drive advancements in nuclear medicine software

15.3.7 REST OF EUROPE

15.4 ASIA PACIFIC

15.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC

15.4.2 JAPAN

15.4.2.1 Deeply ingrained culture of technological advancements in healthcare and medical imaging to support market

15.4.3 CHINA

15.4.3.1 China's strategy for healthcare modernization and technological independence to boost growth

15.4.4 INDIA

15.4.4.1 Steady growth in number of nuclear medicine facilities and SPECT/PET equipment to fuel growth

15.4.5 REST OF ASIA PACIFIC

15.5 LATIN AMERICA

15.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA

15.5.2 BRAZIL

15.5.2.1 Improving healthcare infrastructure to boost procedural volume

15.5.3 MEXICO

15.5.3.1 Increasing focus on digital transformation within healthcare system to support market growth

15.5.4 REST OF LATIN AMERICA

15.6 MIDDLE EAST & AFRICA

15.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA

15.6.2 GCC COUNTRIES

15.6.2.1 Substantial investments and national visions to transform market

15.6.3 REST OF MIDDLE EAST & AFRICA

16 COMPETITIVE LANDSCAPE

16.1 OVERVIEW

16.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

16.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET

16.3 REVENUE ANALYSIS, 2020–2024

16.4 MARKET SHARE ANALYSIS, 2024

16.4.1 GLOBAL MARKET SHARE ANALYSIS FOR PET (POSITRON EMISSION TOMOGRAPHY)

16.4.2 GLOBAL MARKET SHARE ANALYSIS FOR SPECT (SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY)

16.5 BRAND/PRODUCT COMPARISON

16.6 COMPANY VALUATION & FINANCIAL METRICS

16.6.1 FINANCIAL METRICS

16.6.2 COMPANY VALUATION

16.7 MARKET RANKING ANALYSIS

16.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024

- 16.8.1 STARS
- 16.8.2 EMERGING LEADERS
- 16.8.3 PERVASIVE PLAYERS
- 16.8.4 PARTICIPANTS
- 16.8.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
 - 16.8.5.1 Company footprint
 - 16.8.5.2 Region footprint
 - 16.8.5.3 Software type footprint
 - 16.8.5.4 Workflow footprint
 - 16.8.5.5 Integration complexity footprint
 - 16.8.5.6 Application footprint
 - 16.8.5.7 Therapeutic area footprint
 - 16.8.5.8 End-user footprint
- 16.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
 - 16.9.1 PROGRESSIVE COMPANIES
 - 16.9.2 RESPONSIVE COMPANIES
 - 16.9.3 DYNAMIC COMPANIES
 - 16.9.4 STARTING BLOCKS
 - 16.9.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
 - 16.9.5.1 Detailed list of key startups/SMEs
 - 16.9.5.2 Competitive benchmarking of startups/SMEs
- 16.10 COMPETITIVE SCENARIO
 - 16.10.1 PRODUCT LAUNCHES & APPROVALS
 - 16.10.2 DEALS
 - 16.10.3 EXPANSIONS
 - 16.10.4 OTHER DEVELOPMENTS

17 COMPANY PROFILES

- 17.1 KEY PLAYERS
 - 17.1.1 GE HEALTHCARE
 - 17.1.1.1 Business overview
 - 17.1.1.2 Products & services offered
 - 17.1.1.3 Recent developments
 - 17.1.1.3.1 Product launches & approvals
 - 17.1.1.3.2 Deals
 - 17.1.1.3.3 Expansions
 - 17.1.1.4 MnM view
 - 17.1.1.4.1 Right to win

- 17.1.1.4.2 Strategic choices
- 17.1.1.4.3 Weaknesses & competitive threats
- 17.1.2 SIEMENS HEALTHINEERS AG
 - 17.1.2.1 Business overview
 - 17.1.2.2 Products & services offered
 - 17.1.2.3 Recent developments
 - 17.1.2.3.1 Product launches
 - 17.1.2.3.2 Deals
 - 17.1.2.4 MnM view
 - 17.1.2.4.1 Right to win
 - 17.1.2.4.2 Strategic choices
 - 17.1.2.4.3 Weaknesses & competitive threats
- 17.1.3 KONINKLIJKE PHILIPS N.V.
 - 17.1.3.1 Business overview
 - 17.1.3.2 Products & services offered
 - 17.1.3.3 Recent developments
 - 17.1.3.3.1 Product launches
 - 17.1.3.4 MnM view
 - 17.1.3.4.1 Right to win
 - 17.1.3.4.2 Strategic choices
 - 17.1.3.4.3 Weaknesses & competitive threats
- 17.1.4 LANTHEUS
 - 17.1.4.1 Business overview
 - 17.1.4.2 Products & services offered
 - 17.1.4.3 Recent developments
 - 17.1.4.3.1 Deals
 - 17.1.4.3.2 Other developments
 - 17.1.4.4 MnM view
 - 17.1.4.4.1 Right to win
 - 17.1.4.4.2 Strategic choices
 - 17.1.4.4.3 Weaknesses & competitive threats
- 17.1.5 CANON MEDICAL SYSTEMS CORPORATION
 - 17.1.5.1 Business overview
 - 17.1.5.2 Products & services offered
 - 17.1.5.3 Recent developments
 - 17.1.5.3.1 Deals
 - 17.1.5.4 MnM view
 - 17.1.5.4.1 Right to win
 - 17.1.5.4.2 Strategic choices

- 17.1.5.4.3 Weaknesses & competitive threats
- 17.1.6 MIRION TECHNOLOGIES, INC.
 - 17.1.6.1 Business overview
 - 17.1.6.2 Products & services offered
 - 17.1.6.3 Recent developments
 - 17.1.6.3.1 Product launches
 - 17.1.6.3.2 Deals
 - 17.1.6.4 MnM view
 - 17.1.6.4.1 Right to win
 - 17.1.6.4.2 Strategic choices
 - 17.1.6.4.3 Weaknesses & competitive threats
- 17.1.7 BRAINLAB AG
 - 17.1.7.1 Business overview
 - 17.1.7.2 Products & services offered
 - 17.1.7.3 Recent developments
 - 17.1.7.3.1 Product approvals
- 17.1.8 MIRADA MEDICAL LIMITED
 - 17.1.8.1 Business overview
 - 17.1.8.2 Products & services offered
 - 17.1.8.3 Recent developments
 - 17.1.8.3.1 Product approvals
 - 17.1.8.3.2 Deals
- 17.1.9 DOSISOFT SA
 - 17.1.9.1 Business overview
 - 17.1.9.2 Products & services offered
 - 17.1.9.3 Recent developments
 - 17.1.9.3.1 Product approvals
 - 17.1.9.3.2 Deals
- 17.1.10 BRACCO GROUP
 - 17.1.10.1 Business overview
 - 17.1.10.2 Products & services offered
 - 17.1.10.3 Recent developments
 - 17.1.10.3.1 Product launches & approvals
- 17.1.11 HERMES MEDICAL SOLUTIONS
 - 17.1.11.1 Business overview
 - 17.1.11.2 Products & services offered
 - 17.1.11.3 Recent developments
 - 17.1.11.3.1 Product launches & approvals
 - 17.1.11.3.2 Deals

17.1.12 INVIA, LLC

- 17.1.12.1 Business overview
- 17.1.12.2 Products & services offered
- 17.1.12.3 Recent developments
 - 17.1.12.3.1 Product launches
 - 17.1.12.3.2 Deals

17.1.13 MEDISO LTD.

- 17.1.13.1 Business overview
- 17.1.13.2 Products & services offered
- 17.1.13.3 Recent developments
 - 17.1.13.3.1 Product launches & approvals

17.1.14 LABLOGIC SYSTEMS LTD.

- 17.1.14.1 Business overview
- 17.1.14.2 Products & services offered
- 17.1.14.3 Recent developments
 - 17.1.14.3.1 Product approvals

17.1.15 COMECER S.P.A. PRIVATE

- 17.1.15.1 Business overview
- 17.1.15.2 Products & services offered
- 17.1.15.3 Recent developments
 - 17.1.15.3.1 Product updates
 - 17.1.15.3.2 Deals

17.1.16 RAYSEARCH LABORATORIES

- 17.1.16.1 Business overview
- 17.1.16.2 Products & services offered
- 17.1.16.3 Recent developments
 - 17.1.16.3.1 Product launches

17.1.17 ULTRASPECT INC.

- 17.1.17.1 Business overview
- 17.1.17.2 Products & services offered

17.1.18 SECTRA AB

- 17.1.18.1 Business overview
- 17.1.18.2 Products & services offered
- 17.1.18.3 Recent developments
 - 17.1.18.3.1 Product launches
 - 17.1.18.3.2 Deals

17.1.19 AGFA-GEVAERT GROUP

- 17.1.19.1 Business overview
- 17.1.19.2 Products & services offered

17.1.20 PERCEPTIVE

17.1.20.1 Business overview

17.1.20.2 Products & services offered

17.1.20.3 Recent developments

17.1.20.3.1 Product launches

17.1.20.3.2 Deals

17.2 OTHER PLAYERS

17.2.1 SYNTERMED INC.

17.2.2 SEGAMI CORPORATION

17.2.3 VERSANT MEDICAL PHYSICS & RADIATION SAFETY

17.2.4 PIXMEO

17.2.5 PAIRE

17.2.6 SUBTLE MEDICAL, INC.

18 APPENDIX

18.1 DISCUSSION GUIDE

18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL

18.3 CUSTOMIZATION OPTIONS

18.4 RELATED REPORTS

18.5 AUTHOR DETAILS

List Of Tables

LIST OF TABLES

TABLE 1 INCLUSIONS & EXCLUSIONS

TABLE 2 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD

TABLE 3 RISK ASSESSMENT: NUCLEAR MEDICINE SOFTWARE MARKET

TABLE 4 NUCLEAR MEDICINE SOFTWARE MARKET: IMPACT ANALYSIS

TABLE 5 NUCLEAR MEDICINE SOFTWARE MARKET: ROLE IN ECOSYSTEM

TABLE 6 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 7 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 8 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS

TABLE 9 REGULATORY STANDARDS IN NUCLEAR MEDICINE

TABLE 10 REGULATORY REQUIREMENTS IN NORTH AMERICA

TABLE 11 REGULATORY REQUIREMENTS IN EUROPE

TABLE 12 REGULATORY REQUIREMENTS IN ASIA PACIFIC

TABLE 13 REGULATORY REQUIREMENTS IN LATIN AMERICA

TABLE 14 REGULATORY REQUIREMENTS IN MIDDLE EAST & AFRICA

TABLE 15 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY KEY PLAYER (2024)

TABLE 16 AVERAGE SELLING PRICE OF NUCLEAR CARDIOLOGY REPORTING SOFTWARE (2024)

TABLE 17 INDICATIVE PRICE FOR NUCLEAR MEDICINE SOFTWARE, BY REGION (2024)

TABLE 18 NUCLEAR MEDICINE SOFTWARE MARKET: PORTER'S FIVE FORCES ANALYSIS

TABLE 19 JURISDICTION ANALYSIS OF TOP APPLICANT COUNTRIES FOR NUCLEAR MEDICINE SOFTWARE SOLUTIONS

TABLE 20 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)

TABLE 21 KEY BUYING CRITERIA FOR END USERS

TABLE 22 UNMET NEEDS IN NUCLEAR MEDICINE SOFTWARE MARKET

TABLE 23 END-USER EXPECTATIONS IN NUCLEAR MEDICINE SOFTWARE MARKET

TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES

TABLE 25 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 26 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION &

RECONSTRUCTION SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 27 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION & RECONSTRUCTION SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 28 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ANALYSIS & QUANTIFICATION SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 29 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ANALYSIS & QUANTIFICATION SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 30 NUCLEAR MEDICINE SOFTWARE MARKET FOR WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 31 NUCLEAR MEDICINE SOFTWARE MARKET FOR WORKFLOW MANAGEMENT & ORCHESTRATION SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 32 NUCLEAR MEDICINE SOFTWARE MARKET FOR PACS INTEGRATION & DATA MANAGEMENT SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 33 NUCLEAR MEDICINE SOFTWARE MARKET FOR PACS INTEGRATION & DATA MANAGEMENT SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 34 NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING & DOCUMENTATION SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 35 NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING & DOCUMENTATION SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 36 NUCLEAR MEDICINE SOFTWARE MARKET FOR RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 37 NUCLEAR MEDICINE SOFTWARE MARKET FOR RADIOPHARMACEUTICAL MANAGEMENT SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 38 NUCLEAR MEDICINE SOFTWARE MARKET FOR DOSIMETRY & TREATMENT PLANNING SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 39 NUCLEAR MEDICINE SOFTWARE MARKET FOR DOSIMETRY & TREATMENT PLANNING SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 40 NUCLEAR MEDICINE SOFTWARE MARKET FOR QUALITY CONTROL & ASSURANCE SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 41 NUCLEAR MEDICINE SOFTWARE MARKET FOR QUALITY CONTROL & ASSURANCE SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 42 NUCLEAR MEDICINE SOFTWARE MARKET FOR AI & ADVANCED ANALYTICS SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 43 NUCLEAR MEDICINE SOFTWARE MARKET FOR AI & ADVANCED ANALYTICS SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 44 NUCLEAR MEDICINE SOFTWARE MARKET FOR MOBILE & REMOTE ACCESS SOFTWARE: MAJOR PLAYERS AND OFFERINGS

TABLE 45 NUCLEAR MEDICINE SOFTWARE MARKET FOR MOBILE & REMOTE ACCESS SOFTWARE, BY REGION, 2023–2030 (USD MILLION)

TABLE 46 NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 47 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION WORKFLOWS: MAJOR PLAYERS AND OFFERINGS

TABLE 48 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION WORKFLOWS, BY REGION, 2023–2030 (USD MILLION)

TABLE 49 NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA PROCESSING WORKFLOWS: MAJOR PLAYERS AND OFFERINGS

TABLE 50 NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA PROCESSING WORKFLOWS, BY REGION, 2023–2030 (USD MILLION)

TABLE 51 NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING WORKFLOWS: MAJOR PLAYERS AND OFFERINGS

TABLE 52 NUCLEAR MEDICINE SOFTWARE MARKET FOR REPORTING WORKFLOWS, BY REGION, 2023–2030 (USD MILLION)

TABLE 53 NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA MANAGEMENT WORKFLOWS: MAJOR PLAYERS AND OFFERINGS

TABLE 54 NUCLEAR MEDICINE SOFTWARE MARKET FOR DATA MANAGEMENT WORKFLOWS, BY REGION, 2023–2030 (USD MILLION)

TABLE 55 NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 56 NUCLEAR MEDICINE SOFTWARE MARKET FOR STANDALONE SOLUTIONS: MAJOR PLAYERS AND OFFERINGS

TABLE 57 NUCLEAR MEDICINE SOFTWARE MARKET FOR STANDALONE SOLUTIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 58 NUCLEAR MEDICINE SOFTWARE MARKET FOR INTEGRATED SOLUTIONS: MAJOR PLAYERS AND OFFERINGS

TABLE 59 NUCLEAR MEDICINE SOFTWARE MARKET FOR INTEGRATED SOLUTIONS, BY REGION, 2023–2030 (USD MILLION)

TABLE 60 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD-NATIVE PLATFORMS: MAJOR PLAYERS AND OFFERINGS

TABLE 61 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD-NATIVE PLATFORMS, BY REGION, 2023–2030 (USD MILLION)

TABLE 62 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 63 NUCLEAR MEDICINE SOFTWARE MARKET FOR

PERPETUAL/TRADITIONAL LICENSES: MAJOR PLAYERS AND OFFERINGS

TABLE 64 NUCLEAR MEDICINE SOFTWARE MARKET FOR

PERPETUAL/TRADITIONAL LICENSES, BY REGION, 2023–2030 (USD MILLION)

TABLE 65 NUCLEAR MEDICINE SOFTWARE MARKET FOR SUBSCRIPTION/SAAS

LICENSES: MAJOR PLAYERS AND OFFERINGS

TABLE 66 NUCLEAR MEDICINE SOFTWARE MARKET FOR SUBSCRIPTION/SAAS

LICENSES, BY REGION, 2023–2030 (USD MILLION)

TABLE 67 NUCLEAR MEDICINE SOFTWARE MARKET FOR USAGE-BASED

LICENSES: MAJOR PLAYERS AND OFFERINGS

TABLE 68 NUCLEAR MEDICINE SOFTWARE MARKET FOR USAGE-BASED

LICENSES, BY REGION, 2023–2030 (USD MILLION)

TABLE 69 NUCLEAR MEDICINE SOFTWARE MARKET FOR ENTERPRISE

AGREEMENTS: MAJOR PLAYERS AND OFFERINGS

TABLE 70 NUCLEAR MEDICINE SOFTWARE MARKET FOR ENTERPRISE

AGREEMENTS, BY REGION, 2023–2030 (USD MILLION)

TABLE 71 NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL,

2023–2030 (USD MILLION)

TABLE 72 NUCLEAR MEDICINE SOFTWARE MARKET FOR SOFTWARE

LICENSES: MAJOR PLAYERS AND OFFERINGS

TABLE 73 NUCLEAR MEDICINE SOFTWARE MARKET FOR SOFTWARE

LICENSES, BY REGION, 2023–2030 (USD MILLION)

TABLE 74 NUCLEAR MEDICINE SOFTWARE MARKET FOR MAINTENANCE &

SUPPORT SERVICES: MAJOR PLAYERS AND OFFERINGS

TABLE 75 NUCLEAR MEDICINE SOFTWARE MARKET FOR MAINTENANCE &

SUPPORT, BY REGION, 2023–2030 (USD MILLION)

TABLE 76 NUCLEAR MEDICINE SOFTWARE MARKET FOR PROFESSIONAL

SERVICES: MAJOR PLAYERS AND OFFERINGS

TABLE 77 NUCLEAR MEDICINE SOFTWARE MARKET FOR PROFESSIONAL

SERVICES, BY REGION, 2023–2030 (USD MILLION)

TABLE 78 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD SERVICES:

MAJOR PLAYERS AND OFFERINGS

TABLE 79 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD SERVICES, BY

REGION, 2023–2030 (USD MILLION)

TABLE 80 NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION,

2023–2030 (USD MILLION)

TABLE 81 NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC

APPLICATIONS: MAJOR PLAYERS AND OFFERINGS

TABLE 82 NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC

APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

- TABLE 83 NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
- TABLE 84 NUCLEAR MEDICINE SOFTWARE MARKET FOR AUTOMATED IMAGE INTERPRETATION, BY REGION, 2023–2030 (USD MILLION)
- TABLE 85 NUCLEAR MEDICINE SOFTWARE MARKET FOR TUMOR SEGMENTATION & QUANTIFICATION, BY REGION, 2023–2030 (USD MILLION)
- TABLE 86 NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS: MAJOR PLAYERS AND OFFERINGS
- TABLE 87 NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 88 NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
- TABLE 89 NUCLEAR MEDICINE SOFTWARE MARKET FOR PREDICTIVE ANALYTICS, BY REGION, 2023–2030 (USD MILLION)
- TABLE 90 NUCLEAR MEDICINE SOFTWARE MARKET FOR WORKFLOW OPTIMIZATION & QUALITY CONTROL, BY REGION, 2023–2030 (USD MILLION)
- TABLE 91 NUCLEAR MEDICINE SOFTWARE MARKET FOR PERSONALIZED DOSIMETRY CALCULATIONS, BY REGION, 2023–2030 (USD MILLION)
- TABLE 92 NUCLEAR MEDICINE SOFTWARE MARKET FOR THERANOSTICS, BY REGION, 2023–2030 (USD MILLION)
- TABLE 93 NUCLEAR MEDICINE SOFTWARE MARKET FOR EMERGENCY STAT WORKFLOWS: MAJOR PLAYERS AND OFFERINGS
- TABLE 94 NUCLEAR MEDICINE SOFTWARE MARKET FOR EMERGENCY STAT WORKFLOWS, BY REGION, 2023–2030 (USD MILLION)
- TABLE 95 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLINICAL RESEARCH APPLICATIONS: MAJOR PLAYERS AND OFFERINGS
- TABLE 96 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLINICAL RESEARCH APPLICATIONS, BY REGION, 2023–2030 (USD MILLION)
- TABLE 97 NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
- TABLE 98 NUCLEAR MEDICINE SOFTWARE MARKET FOR ONCOLOGY: MAJOR PLAYERS AND OFFERINGS
- TABLE 99 NUCLEAR MEDICINE SOFTWARE MARKET FOR ONCOLOGY, BY REGION, 2023–2030 (USD MILLION)
- TABLE 100 NUCLEAR MEDICINE SOFTWARE MARKET FOR NEUROLOGY: MAJOR PLAYERS AND OFFERINGS
- TABLE 101 NUCLEAR MEDICINE SOFTWARE MARKET FOR NEUROLOGY, BY REGION, 2023–2030 (USD MILLION)
- TABLE 102 NUCLEAR MEDICINE SOFTWARE MARKET FOR CARDIOLOGY:

MAJOR PLAYERS AND OFFERINGS**TABLE 103 NUCLEAR MEDICINE SOFTWARE MARKET FOR CARDIOLOGY, BY REGION, 2023–2030 (USD MILLION)****TABLE 104 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER THERAPEUTIC AREAS: MAJOR PLAYERS AND OFFERINGS****TABLE 105 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2023–2030 (USD MILLION)****TABLE 106 NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)****TABLE 107 NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES: MAJOR PLAYERS AND OFFERINGS****TABLE 108 NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)****TABLE 109 NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)****TABLE 110 NUCLEAR MEDICINE SOFTWARE MARKET FOR AI & ADVANCED ANALYTICS, BY REGION, 2023–2030 (USD MILLION)****TABLE 111 NUCLEAR MEDICINE SOFTWARE MARKET FOR DOSIMETRY & TREATMENT PLANNING, BY REGION, 2023–2030 (USD MILLION)****TABLE 112 NUCLEAR MEDICINE SOFTWARE MARKET FOR CLOUD-NATIVE PLATFORMS TECHNOLOGY, BY REGION, 2023–2030 (USD MILLION)****TABLE 113 NUCLEAR MEDICINE SOFTWARE MARKET FOR MOBILE & REMOTE ACCESS, BY REGION, 2023–2030 (USD MILLION)****TABLE 114 NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)****TABLE 115 NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY REGION, 2023–2030 (USD MILLION)****TABLE 116 NUCLEAR MEDICINE SOFTWARE MARKET FOR IMAGE ACQUISITION & RECONSTRUCTION, BY REGION, 2023–2030 (USD MILLION)****TABLE 117 NUCLEAR MEDICINE SOFTWARE MARKET FOR PACS INTEGRATION, BY REGION, 2023–2030 (USD MILLION)****TABLE 118 NUCLEAR MEDICINE SOFTWARE MARKET FOR QUALITY CONTROL, BY REGION, 2023–2030 (USD MILLION)****TABLE 119 NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)****TABLE 120 NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS: MAJOR PLAYERS AND OFFERINGS****TABLE 121 NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)**

TABLE 122 NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 123 NUCLEAR MEDICINE SOFTWARE MARKET FOR HOSPITALS, BY REGION, 2023–2030 (USD MILLION)

TABLE 124 NUCLEAR MDICINE SOFTWARE MARKET FOR OUTPATIENT SETTINGS, BY REGION, 2023–2030 (USD MILLION)

TABLE 125 NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 126 NUCLEAR MDICINE SOFTWARE MARKET FOR RADIOPHARMACIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 127 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER HEALTHCARE ROVIDERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 128 NUCLEAR MEDICINE SOFTWARE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: MAJOR PLAYERS AND OFFERINGS

TABLE 129 NUCLEAR MEDICINE SOFTWARE MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 130 NUCLEAR MEDICINE SOFTWARE MARKET FOR MEDTECH COMPANIES: MAJOR PLAYERS AND OFFERINGS

TABLE 131 NUCLEAR MEDICINE SOFTWARE MARKET FOR MEDTECH COMPANIES, BY REGION, 2023–2030 (USD MILLION)

TABLE 132 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER END USERS: MAJOR PLAYERS AND OFFERINGS

TABLE 133 NUCLEAR MEDICINE SOFTWARE MARKET FOR OTHER END USERS, BY REGION, 2023–2030 (USD MILLION)

TABLE 134 NUCLEAR MEDICINE SOFTWARE MARKET, BY REGION, 2023–2030 (USD MILLION)

TABLE 135 NORTH AMERICA: MACROECONOMIC OUTLOOK

TABLE 136 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 137 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 138 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 139 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 140 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 141 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

- TABLE 142 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
- TABLE 143 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 144 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 145 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
- TABLE 146 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)
- TABLE 147 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 148 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 149 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
- TABLE 150 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 151 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)
- TABLE 152 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
- TABLE 153 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)
- TABLE 154 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)
- TABLE 155 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)
- TABLE 156 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
- TABLE 157 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 158 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 159 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
- TABLE 160 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)
- TABLE 161 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING

TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 162 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 163 US: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 164 US: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 165 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 166 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 167 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 168 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 169 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 170 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 171 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 172 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 173 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 174 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)

TABLE 175 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 176 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 177 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 178 CANADA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 179 EUROPE: MACROECONOMIC OUTLOOK

TABLE 180 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 181 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE

TYPE, 2023–2030 (USD MILLION)

TABLE 182 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 183 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 184 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 185 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 186 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 187 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 188 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 189 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 190 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)

TABLE 191 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 192 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 193 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 194 EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 195 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 196 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 197 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 198 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 199 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 200 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

- TABLE 201 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 202 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 203 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
- TABLE 204 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)
- TABLE 205 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 206 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 207 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)
- TABLE 208 GERMANY: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 209 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)
- TABLE 210 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)
- TABLE 211 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)
- TABLE 212 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)
- TABLE 213 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)
- TABLE 214 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)
- TABLE 215 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 216 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 217 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)
- TABLE 218 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)
- TABLE 219 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)
- TABLE 220 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE

TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 221 UK: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 222 UK: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 223 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 224 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 225 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 226 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 227 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 228 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 229 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 230 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 231 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 232 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)

TABLE 233 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 234 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 235 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 236 FRANCE: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 237 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 238 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 239 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 240 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 241 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 242 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 243 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 244 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 245 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 246 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)

TABLE 247 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 248 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 249 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 250 ITALY: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 251 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 252 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 253 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 254 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 255 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 256 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 257 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 258 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 259 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC

AREA, 2023–2030 (USD MILLION)

TABLE 260 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)

TABLE 261 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 262 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 263 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 264 SPAIN: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 265 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 266 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 267 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 268 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 269 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 270 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 271 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 272 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 273 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 274 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)

TABLE 275 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 276 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 277 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 278 REST OF EUROPE: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 279 ASIA PACIFIC: MACROECONOMIC OUTLOOK

TABLE 280 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY COUNTRY, 2023–2030 (USD MILLION)

TABLE 281 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 282 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 283 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 284 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 285 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 286 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 287 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 288 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 289 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 290 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)

TABLE 291 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 292 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 293 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 294 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 295 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 296 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 297 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 298 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 299 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 300 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 301 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 302 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 303 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 304 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2023–2030 (USD MILLION)

TABLE 305 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 306 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 307 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 308 JAPAN: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 309 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 310 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 311 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 312 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 313 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 314 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

TABLE 315 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 316 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 317 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2023–2030 (USD MILLION)

TABLE 318 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY

MATURITY, 2023–2030 (USD MILLION)

TABLE 319 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR UPCOMING TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 320 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR MATURE TECHNOLOGIES, BY TYPE, 2023–2030 (USD MILLION)

TABLE 321 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2023–2030 (USD MILLION)

TABLE 322 CHINA: NUCLEAR MEDICINE SOFTWARE MARKET FOR HEALTHCARE PROVIDERS, BY TYPE, 2023–2030 (USD MILLION)

TABLE 323 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2023–2030 (USD MILLION)

TABLE 324 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2023–2030 (USD MILLION)

TABLE 325 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2023–2030 (USD MILLION)

TABLE 326 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2023–2030 (USD MILLION)

TABLE 327 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2023–2030 (USD MILLION)

TABLE 328 INDIA: NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2023–2030 (USD MILLION)

List Of Figures

LIST OF FIGURES

FIGURE 1 NUCLEAR MEDICINE SOFTWARE MARKET SEGMENTATION & REGIONAL SCOPE

FIGURE 2 RESEARCH DESIGN

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING

FIGURE 5 BOTTOM-UP APPROACH

FIGURE 6 TOP-DOWN APPROACH

FIGURE 7 CAGR PROJECTIONS FROM ANALYSIS OF MARKET DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NUCLEAR MEDICINE SOFTWARE INDUSTRY

FIGURE 8 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

FIGURE 9 DATA TRIANGULATION METHODOLOGY

FIGURE 10 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE TYPE, 2025 VS. 2030 (USD MILLION)

FIGURE 11 NUCLEAR MEDICINE SOFTWARE MARKET, BY WORKFLOW, 2025 VS. 2030 (USD MILLION)

FIGURE 12 NUCLEAR MEDICINE SOFTWARE MARKET, BY INTEGRATION COMPLEXITY, 2025 VS. 2030 (USD MILLION)

FIGURE 13 NUCLEAR MEDICINE SOFTWARE MARKET, BY SOFTWARE LICENSING, 2025 VS. 2030 (USD MILLION)

FIGURE 14 NUCLEAR MEDICINE SOFTWARE MARKET, BY REVENUE MODEL, 2025 VS. 2030 (USD MILLION)

FIGURE 15 NUCLEAR MEDICINE SOFTWARE MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)

FIGURE 16 NUCLEAR MEDICINE SOFTWARE MARKET, BY THERAPEUTIC AREA, 2025 VS. 2030 (USD MILLION)

FIGURE 17 NUCLEAR MEDICINE SOFTWARE MARKET, BY TECHNOLOGY MATURITY, 2025 VS. 2030 (USD MILLION)

FIGURE 18 NUCLEAR MEDICINE SOFTWARE MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)

FIGURE 19 NUCLEAR MEDICINE SOFTWARE MARKET: REGIONAL SNAPSHOT

FIGURE 20 GROWING ADOPTION OF ADVANCED IMAGING MODALITIES, ENHANCED INTEROPERABILITY, AND EXPANSION OF REMOTE ACCESS TO DRIVE MARKET GROWTH

FIGURE 21 INTEGRATED SOLUTIONS SEGMENT AND JAPAN TO COMMAND

LARGEST SHARES OF ASIA PACIFIC MARKET IN 2024

FIGURE 22 MARKET IN CHINA TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD

FIGURE 23 ASIA PACIFIC TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD

FIGURE 24 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD

FIGURE 25 MARKET DYNAMICS: NUCLEAR MEDICINE SOFTWARE MARKET

FIGURE 26 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

FIGURE 27 NUCLEAR MEDICINE SOFTWARE MARKET: ECOSYSTEM ANALYSIS

FIGURE 28 NUCLEAR MEDICINE SOFTWARE MARKET: SUPPLY CHAIN ANALYSIS

FIGURE 29 NUCLEAR MEDICINE SOFTWARE: PORTER'S FIVE FORCES ANALYSIS

FIGURE 30 JURISDICTION AND TOP APPLICANT ANALYSIS OF NUCLEAR MEDICINE SOFTWARE SOLUTIONS

FIGURE 31 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR NUCLEAR MEDICINE SOFTWARE MARKET (JANUARY 2015 TO MAY 2025)

FIGURE 32 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS

FIGURE 33 KEY BUYING CRITERIA FOR END USERS

FIGURE 34 INVESTOR DEALS AND FUNDING IN NUCLEAR MEDICINE SOFTWARE MARKET

FIGURE 35 MARKET POTENTIAL OF AI/GENERATIVE AI ON NUCLEAR MEDICINE SOFTWARE SOLUTIONS ACROSS INDUSTRIES

FIGURE 36 PRICE IMPACT ANALYSIS

FIGURE 37 NORTH AMERICA: NUCLEAR MEDICINE SOFTWARE MARKET SNAPSHOT

FIGURE 38 ASIA PACIFIC: NUCLEAR MEDICINE SOFTWARE MARKET SNAPSHOT

FIGURE 39 REVENUE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET, 2020–2024

FIGURE 40 MARKET SHARE ANALYSIS OF KEY PLAYERS IN NUCLEAR MEDICINE SOFTWARE MARKET, 2024

FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PET SOFTWARE MARKET, 2024

FIGURE 42 MARKET SHARE ANALYSIS OF KEY PLAYERS IN SPECT SOFTWARE MARKET, 2024

FIGURE 43 NUCLEAR MEDICINE SOFTWARE MARKET: BRAND/SOFTWARE COMPARITIVE ANALYSIS

FIGURE 44 EV/EBITDA OF KEY VENDORS

FIGURE 45 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK

BETA

FIGURE 46 NUCLEAR MEDICINE SOFTWARE MARKET: KEY PLAYERS, 2024

FIGURE 47 NUCLEAR MEDICINE SOFTWARE MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024

FIGURE 48 NUCLEAR MEDICINE SOFTWARE MARKET: COMPANY FOOTPRINT

FIGURE 49 NUCLEAR MEDICINE SOFTWARE MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024

FIGURE 50 GE HEALTHCARE: COMPANY SNAPSHOT (2024)

FIGURE 51 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)

FIGURE 52 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2024)

FIGURE 53 LANTHEUS: COMPANY SNAPSHOT (2024)

FIGURE 54 CANON MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2024)

FIGURE 55 MIRION TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2024)

FIGURE 56 RAYSEARCH LABORATORIES: COMPANY SNAPSHOT (2024)

FIGURE 57 SECTRA AB: COMPANY SNAPSHOT (2024)

FIGURE 58 AGFA-GEVAERT GROUP: COMPANY SNAPSHOT (2024)

I would like to order

Product name: Nuclear Medicine Software Market by Software (Image Management, Workflow, PACS, Dosimetry, Treatment, AI/Analytics), Application (Diagnosis, Treatment, Theranostics, Research), Disease (Onco, Neuro, Cardio), End User & Region - Global Forecast to 2030

Product link: <https://marketpublishers.com/r/N6E36520B749EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/N6E36520B749EN.html>